[go: up one dir, main page]

WO2008060368A3 - Transglutaminase-binding peptides and methods of use - Google Patents

Transglutaminase-binding peptides and methods of use Download PDF

Info

Publication number
WO2008060368A3
WO2008060368A3 PCT/US2007/021163 US2007021163W WO2008060368A3 WO 2008060368 A3 WO2008060368 A3 WO 2008060368A3 US 2007021163 W US2007021163 W US 2007021163W WO 2008060368 A3 WO2008060368 A3 WO 2008060368A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
transglutaminase
binding peptides
compositions
subject matter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/021163
Other languages
French (fr)
Other versions
WO2008060368A2 (en
Inventor
Mark W Dewhirst
Zahid N Rabbani
Zeljko Vujaskovic
Charles S Greenberg
John C Kirkpatrick
Hong Yuan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of WO2008060368A2 publication Critical patent/WO2008060368A2/en
Publication of WO2008060368A3 publication Critical patent/WO2008060368A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The presently disclosed subject matter discloses diagnostic and prognostic techniques and compositions for the detection and evaluation of a pathologic disorder. Particularly, the presently disclosed subject matter relates to compositions and methods for evaluating the presence of transglutaminase expression in a pathologic condition compared to normal, healthy expression to diagnose, treat and effectively monitor the pathologic condition.
PCT/US2007/021163 2006-10-02 2007-10-02 Transglutaminase-binding peptides and methods of use Ceased WO2008060368A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84871006P 2006-10-02 2006-10-02
US60/848,710 2006-10-02

Publications (2)

Publication Number Publication Date
WO2008060368A2 WO2008060368A2 (en) 2008-05-22
WO2008060368A3 true WO2008060368A3 (en) 2008-09-25

Family

ID=39402167

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/021163 Ceased WO2008060368A2 (en) 2006-10-02 2007-10-02 Transglutaminase-binding peptides and methods of use

Country Status (1)

Country Link
WO (1) WO2008060368A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060052308A1 (en) * 2003-11-18 2006-03-09 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof
US20060083689A1 (en) * 2001-01-05 2006-04-20 Duke University Contrast enhancement agent for magnetic resonance imaging
US7049289B1 (en) * 1998-05-15 2006-05-23 Amersham Plc Labelled glutamine and lysine analogues

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7049289B1 (en) * 1998-05-15 2006-05-23 Amersham Plc Labelled glutamine and lysine analogues
US20060083689A1 (en) * 2001-01-05 2006-04-20 Duke University Contrast enhancement agent for magnetic resonance imaging
US20060052308A1 (en) * 2003-11-18 2006-03-09 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof

Also Published As

Publication number Publication date
WO2008060368A2 (en) 2008-05-22

Similar Documents

Publication Publication Date Title
EP2767833A3 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2539712A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MX341191B (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure.
WO2011015944A3 (en) Use of free dna as an early predictor of severity in acute pancreatitis
NZ592358A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure using tissue inhibitor of metalloproteinase 2 (timp-2)
WO2008063527A8 (en) Detection of deception and truth-telling using fmri of the brain
WO2008073627A3 (en) Method of diagnosing and treating asthma
EP2811036A3 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2006042075A3 (en) System and methods for assessing the neuromuscular pathway prior to nerve testing
EP3296406A3 (en) Mirna fingerprint in the diagnosis of lung cancer
WO2011064225A8 (en) Novel diagnostic method for the diagnosis of alzheimer's disease or mild cognitive impairment
WO2012008807A3 (en) Use of tgase2 and vhl as a diagnostic marker for renal cell carcinoma
WO2012129309A3 (en) Extended smart diagnostic cleat
WO2008009751A3 (en) Transcription infidelity, detection and uses thereof
MX2009013649A (en) Genetic variants on chr 15q24 as markers for use in diagnosis, prognosis and treatment of exfoliation syndrome and glaucoma.
WO2008089072A3 (en) Proteomic profiling method useful for condition diagnosis and monitoring, composition screening, and therapeutic monitoring
WO2007061906A3 (en) Diagnostic and therapeutics for cardiovascular disorders
WO2010041046A8 (en) Granin proteins as markers of heart disease
WO2007028162A3 (en) Methods and compositions for identifying biomarkers useful in diagnosis and/or treatment of biological states
WO2010046648A3 (en) Diagnostic test for streptococcus equi
WO2008033427A3 (en) Compositions and methods for detection of lysosomal storage disease
WO2012017430A3 (en) Microrna patterns for the diagnosis, prognosis and treatment of melanoma
WO2007084397A3 (en) Processing of slpi by chymase
WO2005116076A3 (en) Neoplasm-specific polypeptides and their uses
NZ608316A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07861384

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07861384

Country of ref document: EP

Kind code of ref document: A2